Johnson & Johnson (JNJ) disclosed two major biopharmaceutical initiatives on July 29 local time, involving total capital commitments of approximately $3.6 billion. On the one hand, the company announced a collaboration with Sail Biomedicines to advance in vivo CAR-T therapy programs and secured an exclusive option to acquire Sail for $2.58 billion. On the same day, the company also announced the completion of its $1 billion cash acquisition of Firefly Bio to help drive next-generation innovative oncology R&D. Johnson & Johnson’s stock price has risen nearly 30% so far this year.
Under the agreement between Johnson & Johnson and Sail, the company will pay total upfront consideration of $785 million, comprising $465 million in equity investment and $140 million in potential development milestone payments. If Johnson & Johnson exercises its acquisition option, it will pay an additional $2.58 billion. Public information shows that Sail, founded in 2023, focuses on developing novel RNA molecules that can act directly in vivo. Its core technology uses nanoparticle delivery systems to deliver RNA to human immune cells for reprogramming, offering hope for curing autoimmune diseases. Johnson & Johnson believes that in vivo CAR-T therapy is one of the most promising cutting-edge technologies in medicine, with the potential to provide transformative treatment options for multiple cancers and immune-mediated diseases. Meanwhile, the acquisition of Firefly Bio will further enhance Johnson & Johnson’s capabilities in next-generation antibody engineering and expand its strategic positioning for addressing complex tumor biology.
Johnson & Johnson estimates that if it exercises the acquisition option for Sail, the agreement will dilute adjusted earnings per share by approximately $0.18 in 2026 and $1.28 in 2027. The acquisition of Firefly Bio is expected to generate approximately $1 billion in research and development expenses in the third quarter of 2026, and dilute adjusted earnings per share by approximately $0.46 in 2026 and $0.08 in 2027.
The continued expansion of the new drug landscape is providing strong support for Johnson & Johnson’s performance growth. Financial reports show that the company’s second-quarter revenue reached $25.31 billion, up 6.6% year-over-year, with non-GAAP earnings per share of $2.90, both exceeding market expectations. Among them, the innovative medicine business segment posted revenue growth of 7.8% year-over-year to approximately $16.4 billion. Performance growth was primarily driven by the oncology division, with global sales of its anticancer drug daratumumab rising nearly 19% in the second quarter.
Although most investors still associate Johnson & Johnson with consumer brands such as Tylenol and Band-Aid, the company spun off those brands into the independent company Kenvue in 2023, refocusing its business on prescription pharmaceuticals and medical devices. Currently, Johnson & Johnson aims to achieve at least $50 billion in annual cancer drug sales by 2030, positioning itself as a leader in the field. The company’s overall revenue is expected to exceed $100 billion for the first time this year. Although the anti-inflammatory drug Stelara faces sales pressure due to patent expirations, the nearly 20% sustained growth in oncology business will effectively offset that impact.
It is precisely this oncology-driven revenue growth that lays the foundation for Johnson & Johnson to extend its legendary “Dividend King” record. The company has increased its per-share dividend for 64 consecutive years. Facing the broad prospect that the global cancer treatment market is expected to maintain an average annual growth rate of 11.3% through 2035, Johnson & Johnson is striving to capture its due share of this incremental space.
